BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11244326)

  • 1. Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates?
    Nikolic-Tomasević Z; Jelic S; Popov I; Radosavljević D; Mitrović L
    Oncology; 2001; 60(2):123-6. PubMed ID: 11244326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage.
    Arumugam GP; Sundravel S; Shanthi P; Sachdanandam P
    J Bone Miner Metab; 2006; 24(3):243-7. PubMed ID: 16622738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of gallium nitrate on tamoxifen induced hypercalcemia in rats bearing mammary tumor.
    Arumugam G; Shanthi P; Sachdanandam P
    Exp Oncol; 2006 Jun; 28(2):141-5. PubMed ID: 16837906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Two cases of stage IV breast cancer with severe hypercalcemia].
    Ohsako T; Yamamoto Y; Kawazoe T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O; Sakamoto N; Iwase H
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):223-6. PubMed ID: 16484860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-threatening tamoxifen-induced hypercalcaemia.
    Mulvenna PM; Wright AJ; Podd TJ
    Clin Oncol (R Coll Radiol); 1999; 11(3):193-5. PubMed ID: 10465476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
    Nesković-Konstantinović Z; Mitrović L; Petrović J; Stamatović L; Ristović Z
    Support Care Cancer; 1995 Nov; 3(6):422-4. PubMed ID: 8564348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin].
    Kusama M; Kaise H; Nakayama S; Ota D; Aoki T; Koyanagi Y; Matsunaga T; Nakamura Y
    Gan To Kagaku Ryoho; 2000 May; 27(5):763-6. PubMed ID: 10832449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen-related vasculitis.
    Baptista MZ; Prieto VG; Chon S; Hortobagyi GN; Esteva FJ
    J Clin Oncol; 2006 Jul; 24(21):3504-5. PubMed ID: 16849770
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
    Hassan BA; Yusoff ZB; Hassali MA; Othman SB; Weiderpass E
    Asian Pac J Cancer Prev; 2012; 13(9):4373-8. PubMed ID: 23167346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer.
    Rosenberg SM; Partridge AH
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307642
    [No Abstract]   [Full Text] [Related]  

  • 14. Tamoxifen-induced hypercalcemia in breast cancer.
    Legha SS; Powell K; Buzdar AU; Blumenschein GR
    Cancer; 1981 Jun; 47(12):2803-6. PubMed ID: 7260871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
    Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
    Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of using Aredia for hypercalcemia in oncology patients].
    Lichinitser MR; Vyshinskaia GV; Kupchan DZ; Liubimova NV
    Ter Arkh; 1993; 65(9):80-1. PubMed ID: 8303606
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypercalcemia and childhood cancer: a 7-year experience.
    Kerdudo C; Aerts I; Fattet S; Chevret L; Pacquement H; Doz F; Michon J; Garabedian M; Orbach D
    J Pediatr Hematol Oncol; 2005 Jan; 27(1):23-7. PubMed ID: 15654274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates in the prevention and treatment of bone metastases.
    Ramaswamy B; Shapiro CL
    Oncology (Williston Park); 2003 Sep; 17(9):1261-70; discussion 1270-2, 1277-8, 1280. PubMed ID: 14569853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.